Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies

The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations

(2019) Cristina Valencia-Sanchez et al.   Multiple Sclerosis Journal

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review

(2019) Tjalf Ziemssen et al.   Frontiers in Neurology

Autonomic symptom burden can predict disease activity in early multiple sclerosis

(2019) Magdalena Krbot Skorić et al.   Multiple Sclerosis and Related Disorders

Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study

(2019) Niklas Frahm et al.   PLoS One

Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis

(2019) Robert Hermann et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Immune and autonomic nervous system interactions in multiple sclerosis: clinical implications

(2019) Mario Habek   CLINICAL AUTONOMIC RESEARCH

Longitudinal assessment of autonomic nervous system in patients with first demyelinating event suggestive of multiple sclerosis

(2019) Mario Habek et al.   EUROPEAN JOURNAL OF NEUROLOGY

Capturing fatigue parameters: The impact of vagal processing in multiple sclerosis related cognitive fatigue

(2019) Carina Sander et al.   Multiple Sclerosis and Related Disorders

Recurrent atrial fibrillation after pulse corticosteroid treatment for a relapse of multiple sclerosis

(2019) Tin Pavičić et al.   Multiple Sclerosis and Related Disorders

Cerebral lesion correlates of sympathetic cardiovascular activation in multiple sclerosis

(2019) Klemens Winder et al.   HUMAN BRAIN MAPPING

Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod

(2019) Emilio Vanoli et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

(2019) Giancarlo Comi et al.   LANCET NEUROLOGY

Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod

(2019) Julia Feige et al.   Multiple Sclerosis and Related Disorders

Progressive multiple sclerosis patients have a higher burden of autonomic dysfunction compared to relapsing remitting phenotype

(2018) Ivan Adamec et al.   CLINICAL NEUROPHYSIOLOGY

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Cardiac repolarization evolves differently during the course of benign and disabling multiple sclerosis

(2018) Alma Mikkola et al.   Multiple Sclerosis and Related Disorders

Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis

(2018) Ruken Özge Akbulak et al.   Multiple Sclerosis and Related Disorders

Characterisation of cardiac autonomic function in multiple sclerosis based on spontaneous changes of heart rate and blood pressure

(2018) Fatemeh Shirbani et al.   Multiple Sclerosis and Related Disorders

Cardiac autonomic function during postural changes and exercise in people with multiple sclerosis: A cross-sectional study

(2018) Elisa Gervasoni et al.   Multiple Sclerosis and Related Disorders

Heart rate variability analysis in patients with multiple sclerosis

(2018) Ozbek Damla et al.   Multiple Sclerosis and Related Disorders

Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigue

(2018) Magdalena Krbot Skorić et al.   CLINICAL AUTONOMIC RESEARCH

Multiple Sclerosis Relapse Presenting as an Acute Cardiomyopathy

(2018) Alina D. Bayer et al.   Multiple Sclerosis and Related Disorders

Reverse takotsubo cardiomyopathy triggered by a multiple sclerosis relapse

(2018) Frédéric London et al.   ACTA NEUROLOGICA BELGICA

Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?

(2018) Duygu Kocyigit et al.   Multiple Sclerosis and Related Disorders

Takotsubo syndrome triggered in the setting of multiple sclerosis: The need to monitor blood catecholamines and the CNS sympathetic input to the heart

(2018) John E. Madias   Multiple Sclerosis and Related Disorders

QTc interval in patients with multiple sclerosis: an inference from the insula of Reil?

(2017) G. Turri et al.   EUROPEAN JOURNAL OF NEUROLOGY

Heart rate variability decreases after 3 months of sustained treatment with fingolimod

(2017) Jochen Vehoff et al.   JOURNAL OF NEUROLOGY

Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab

(2017) E. Nerrant et al.   REVUE NEUROLOGIQUE

The impact of multiple sclerosis onset symptom on cardiac repolarization

(2017) Alma Mikkola et al.   Brain and Behavior

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis

(2017) Kai Li et al.   Frontiers in Neuroscience

Sympathetic cardiovascular and sudomotor functions are frequently affected in early multiple sclerosis

(2016) Mario Habek et al.   CLINICAL AUTONOMIC RESEARCH

Impaired carotid baroreflex control of arterial blood pressure in multiple sclerosis

(2016) Mu Huang et al.   JOURNAL OF NEUROPHYSIOLOGY

Autonomic dysfunction in multiple sclerosis is better detected by heart rate variability and is not correlated with central autonomic network damage

(2016) Gonçalo Videira et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Wpływ leczenia mitoksantronem na serce u chorych na stwardnienie rozsiane

(2016) Żanna Pastuszak et al.   Kardiologia Polska

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

(2016) Jeffrey A Cohen et al.   LANCET NEUROLOGY

An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy

(2016) Luciana Midaglia et al.   Multiple Sclerosis Journal

Cardiac stunning as first manifestation of multiple sclerosis: A case report reminding us not to overlook cardiovascular autonomic dysfunction in multiple sclerosis

(2016) Max J Hilz   Multiple Sclerosis Journal

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis

(2016) Ludwig Kappos et al.   JAMA Neurology

An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy

(2016) Luciana Midaglia et al.   Multiple Sclerosis Journal

Cardiac stunning as first manifestation of multiple sclerosis: A case report reminding us not to overlook cardiovascular autonomic dysfunction in multiple sclerosis

(2016) Max J Hilz   Multiple Sclerosis Journal

Delayed cardiac dysrhythmias after fingolimod administration

(2015) Jamie M. Rosini et al.   AMERICAN JOURNAL OF EMERGENCY MEDICINE

Autonomic dysfunction in multiple sclerosis

(2015) Juan Manuel Racosta et al.   AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL

Autonomic dysfunction, immune regulation, and multiple sclerosis

(2015) Juan Manuel Racosta et al.   CLINICAL AUTONOMIC RESEARCH

Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study

(2015) Damiano Paolicelli et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis

(2015) Tamara Castillo-Trivino et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis

(2015) Sakari Simula et al.   Multiple Sclerosis Journal

Cardiovascular Dysfunction in Multiple Sclerosis

(2015) Tamara B. Kaplan et al.   NEUROLOGIST

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial

(2015) L. Kappos et al.   NEUROLOGY

Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing

(2015) Max J. Hilz et al.   PLoS One

Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis

(2015) Sakari Simula et al.   Multiple Sclerosis Journal

Cardiovascular autonomic dysfunction in multiple sclerosis: A meta-analysis

(2015) Juan Manuel Racosta et al.   Multiple Sclerosis and Related Disorders

Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications

(2014) John Camm et al.   AMERICAN HEART JOURNAL

The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis

(2014) Yara Dadalti Fragoso et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

(2014) Alice Laroni et al.   BMC Neurology

Newly Onset Sinus Bradycardia in the Context of Multiple Sclerosis Relapse

(2014) Sandra Jurić et al.   INTERNAL MEDICINE

Transvascular Autonomic Modulation: A Modified Balloon Angioplasty Technique for the Treatment of Autonomic Dysfunction in Multiple Sclerosis Patients

(2014) Michael Arata et al.   JOURNAL OF ENDOVASCULAR THERAPY

Reduced spontaneous sympathetic nerve activity in multiple sclerosis patients

(2014) David M. Keller et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

The autonomic balance predicts cardiac responses after the first dose of fingolimod

(2014) S Rossi et al.   Multiple Sclerosis Journal

Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation

(2014) Yukihiro Yagi et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

P wave duration and dispersion and QT interval in multiple sclerosis

(2014) Nazanin Razazian et al.   Multiple Sclerosis and Related Disorders

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

(2014) John P. DiMarco et al.   Multiple Sclerosis and Related Disorders

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

(2014) Ludwig Kappos et al.   Multiple Sclerosis and Related Disorders

Symptomatic Sinus Bradycardia After a Treatment Course Of High-dose Oral Prednisone

(2013) Mark R. Taylor et al.   JOURNAL OF EMERGENCY MEDICINE

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

(2013) Ralf Gold et al.   JOURNAL OF NEUROLOGY

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

(2013) Krzysztof Selmaj et al.   LANCET NEUROLOGY

Mortality in patients with multiple sclerosis

(2013) A. Scalfari et al.   NEUROLOGY

Autonomic Dysfunction Presenting as Postural Orthostatic Tachycardia Syndrome in Patients with Multiple Sclerosis

(2012) Khalil Kanjwal et al.   International Journal of Medical Sciences

Early tolerability and safety of fingolimod in clinical practice

(2012) Daniel Ontaneda et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Sudden unexpected death on fingolimod

(2012) JW Lindsey et al.   Multiple Sclerosis Journal

Association of a deficit of arousal with fatigue in multiple sclerosis: Effect of modafinil

(2012) Graham Niepel et al.   NEUROPHARMACOLOGY

Cardiac arrhythmia induced by interferon beta-1a

(2011) Sarrah Kastalli et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Incidence of various cardiac arrhythmias and conduction disturbances due to high dose intravenous methylprednisolone in patients with multiple sclerosis

(2011) Ali Vasheghani-Farahani et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Delayed fingolimod-associated asystole

(2011) Patricio S Espinosa et al.   Multiple Sclerosis Journal

Heart rate variability in multiple sclerosis during a stable phase

(2010) J. A. Monge-Argilés et al.   ACTA NEUROLOGICA SCANDINAVICA

Power spectrum analysis contribution to the detection of cardiovascular dysautonomia in multiple sclerosis

(2010) M. Frontoni et al.   ACTA NEUROLOGICA SCANDINAVICA

Risk of Arterial Cardiovascular Diseases in Patients with Multiple Sclerosis: A Population-Based Cohort Study

(2010) Christian Fynbo Christiansen et al.   NEUROEPIDEMIOLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Variable Effects of Physical Training of Heart Rate Variability, Heart Rate Recovery, and Heart Rate Turbulence in Chronic Heart Failure

(2009) EWA PIOTROWICZ et al.   PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY